NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells

17Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

Abstract

PTEN (Phosphatase and tensin homolog) is a tumour suppressor gene commonly defective in human cancer, and is thus a potentially important therapeutic target. Targeting tumour suppressor loss-of-function is possible by exploiting the genetic concept of synthetic lethality (SL). By combining the use of isogenic models of PTEN deficiency with high-throughput RNA interference (RNAi) screening, we have identified Nemo-Like Kinase (NLK) inhibition as being synthetically lethal with PTEN deficiency. This SL is likely mediated by the transcription factor FOXO1 (Forkhead box O1), an NLK substrate, as the selectivity of NLK gene silencing for PTEN deficient cells can be reversed by FOXO1 knockdown. In addition, we provide evidence that PTEN defective cells targeted by NLK gene depletion undergo senescence, suggesting that NLK function is critical for the continued proliferation of PTEN deficient cells. Taken together, these data provide new insight into the potential of targeting of NLK to treat a range of tumourigenic conditions characterised by PTEN deficiency. © 2012 Mendes-Pereira et al.

Cite

CITATION STYLE

APA

Mendes-Pereira, A. M., Lord, C. J., & Ashworth, A. (2012). NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells. PLoS ONE, 7(10). https://doi.org/10.1371/journal.pone.0047249

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free